Jose R. Arribas

Best Publications

• Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

  Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  4700
  Citations

• Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

  Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  1220
  Citations

• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

  Sharon Walmsley;Barry Bernstein;Martin King;José Arribas

  863
  Citations

• Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

  Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  473
  Citations

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  416
  Citations

• Clinical Management of Ebola Virus Disease in the United States and Europe.

  Timothy M. Uyeki;Aneesh K. Mehta;Richard T. Davey;Allison M. Liddell

  411
  Citations

• Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

  Jan van Lunzen;Franco Maggiolo;José R Arribas;Aza Rakhmanova

  395
  Citations

• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

  Anthony Mills;Jose R. Arribas;Jaime Andrade-Villanueva;Giovanni DiPerri

  375
  Citations

• Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

  Alberto M Borobia;Antonio J Carcas;Mayte Pérez-Olmeda;Luis Castaño

  369
  Citations

• Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.

  Julia Del Amo;Rosa Polo;Santiago Moreno;Asunción Díaz

  356
  Citations

• Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

  Jose R. Arribas;Anton L. Pozniak;Joel E. Gallant;Edwin DeJesus

  338
  Citations

• Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

  Anton L. Pozniak;Joel E. Gallant;Joel E. Gallant;Edwin DeJesus;Jose R. Arribas;Jose R. Arribas

  317
  Citations

• Smoking-Related Health Risks Among Persons With HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial

  Alan R. Lifson;Jacqueline Neuhaus;Jose Ramon Arribas;Mary van den Berg-Wolf

  314
  Citations

• A cohort of patients with COVID-19 in a major teaching hospital in Europe

  Alberto M Borobia;Antonio J Carcas;Francisco Arnalich;Rodolfo Álvarez-Sala

  281
  Citations

• Pegylated Ifn-α2b plus ribavirin as therapy for chronic hepatitis C in Hiv-infected patients

  Mayte Pérez-Olmeda;Marina Núñez;Miriam Romero;Juan González

  281
  Citations

• Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

  Anton Pozniak;Jose R. Arribas;Joseph Gathe;Samir K. Gupta

  258
  Citations

• Severe Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the Literature

  Vicente Falcó;Dolors Rodríguez;Esteban Ribera;Esteban Martínez

  255
  Citations

• Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

  Nicholas I. Paton;Cissy Kityo;Anne Hoppe;Andrew Reid

  236
  Citations

• Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications.

  Juan R Rey;Juan Caro‐Codón;Sandra O. Rosillo;Ángel M. Iniesta

  236
  Citations

• Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

  Joseph J. Eron;Jürgen K. Rockstroh;Jacques Reynes;Jaime Andrade-Villanueva

  228
  Citations